Drug Trial Radar · NCT05629585
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,174
Actual
Start
Nov 28, 2022
Primary completion
Sep 1, 2027
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo; SWOG Clinical Trials Partnerships, LLC
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Conditions
- Breast Cancer
Interventions
Dato-DXdDrug
Experimental drug. Provided in 100mg vials. IV infusion
DurvalumabDrug
Experimental drug. Provided in 50mg vials. IV infusion
CapecitabineDrug
Active Comparator. Tablet. Oral route of administration
PembrolizumabDrug
Active Comparator. Provided in 100mg vials. IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICTTime frame: From randomisation to date of the event, up to 57 months from first subject in
Locations
276 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Springdale, Arkansas
Research Site
Beverly Hills, California
Research Site
Costa Mesa, California
Research Site
Duarte, California
Research Site
Fountain Valley, California
Research Site
Irvine, California
Research Site
La Jolla, California
Research Site
Lakewood, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Newport Beach, California
Research Site
Orange, California
Research Site
Roseville, California
Research Site
Upland, California
Research Site
Vallejo, California
Research Site
Denver, Colorado
Research Site
New Haven, Connecticut
Research Site
Newark, Delaware
Research Site
Washington D.C., District of Columbia
Research Site
Altamonte Springs, Florida
Research Site
Hollywood, Florida
Research Site
Miami Beach, Florida
Research Site
Tallahassee, Florida
Research Site
West Palm Beach, Florida
Research Site
Athens, Georgia
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Maywood, Illinois
Research Site
Westwood, Kansas
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Louisville, Kentucky
Research Site
Louisville, Kentucky
Showing 40 of 276 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.